Histologically confirmed invasive breast cancer (stages I-III).
Indication for neoadjuvant or adjuvant chemotherapy containing an anthracycline or a taxane.
Targeted therapies and hormone therapy are permitted according to clinical indication.
Ability to provide informed consent and comply with study procedures.
ECOG performance status 0-2.
Ability to maintain adequate hydration.
You may not be if
Prior neurologic conditions that may impair cognitive assessment, including previous stroke, dementia, traumatic brain injury with neurologic sequelae, or other neurologic disorders affecting cognition.
Uncorrected sensory impairments that preclude cognitive assessment and/or completion of study instruments.
History of uncontrolled psychiatric disorders that may interfere with cognitive evaluation.
Creatinine clearance \<60 mL/min, calculated using the Cockcroft-Gault formula.
Known liver disease.
Pregnancy.
Heart failure.
Presence of ascites.
Inflammatory bowel disease.
Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).
Lactation.
Chronic use of immunosuppressive agents, including doses greater than 10 mg/day or equivalent.
Prior chronic creatine supplementation within the last 3 months.
Known allergy to any component of the supplement or placebo.
Clareo Health | Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment
